Last reviewed · How we verify
Rasagiline Tablets
At a glance
| Generic name | Rasagiline Tablets |
|---|---|
| Sponsor | Guangzhou Henovcom Bioscience Co. Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Effect of Rasagiline on Balance in Parkinson's Disease as Measured by Computerized Posturography (PHASE4)
- Relative Bioavailability Study of HNC364 Injectable Suspension (PHASE1)
- Rasagiline Tablets Special Drug Use-Results Survey "Survey on Long-term Safety"
- Image Parkinson's Disease Progression Study (PHASE2)
- Azilect® In Wearing-Off (AIWO)
- A Phase 3 Study With P2B001 in Subjects With Early Parkinson's (PHASE3)
- Parallel-Group Study to Assess the Effect of Rasagiline on Cognition in Patients With Parkinson's Disease (PHASE4)
- Rasagiline Rescue in Alzheimer's Disease Clinical Trial (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rasagiline Tablets CI brief — competitive landscape report
- Rasagiline Tablets updates RSS · CI watch RSS
- Guangzhou Henovcom Bioscience Co. Ltd. portfolio CI